We aimed to assess the effects on mortality, viral suppression, and other health outcomes and quality indicators of the Streamlining Tasks and Roles to Expand Treatment and Care for HIV (STRETCH) programme, Erastin purchase which provides educational outreach training of nurses to initiate and represcribe ART, and to decentralise care.
Methods We undertook a pragmatic, parallel, cluster-randomised trial in South Africa between Jan 28, 2008, and June 30, 2010. We randomly assigned 31 primary-care ART clinics to implement the STRETCH programme (intervention group) or to continue with standard care (control group). The ratio of randomisation depended on how many clinics were in each of nine strata. Two cohorts were
enrolled: eligible patients in cohort Nepicastat nmr 1 were adults (aged >= 16 years) with CD4 counts of 350 cells per mu L or less
who were not receiving ART; those in cohort 2 were adults who had already received ART for at least 6 months and were being treated at enrolment. The primary outcome in cohort 1 was time to death (superiority analysis). The primary outcome in cohort 2 was the proportion with undetectable viral loads (<400 copies per mL) 12 months after enrolment (equivalence analysis, prespecified difference <6%). Patients and clinicians could not be masked to group assignment. The interim analysis was blind, but data analysts were not masked after the database was locked for final analysis. Analyses were done by intention to find more treat. This trial is registered, number ISRCTN46836853.
Findings 5390 patients in cohort 1 and 3029 in cohort 2 were in the intervention group, and 3862 in cohort 1 and 3202 in cohort 2 were in the control group. Median follow-up was 16.3 months (IQR 12.2-18.0) in cohort 1 and 18.0 months (18.0-18.0) in cohort 2. In cohort 1, 997 (20%) of 4943 patients analysed
in the intervention group and 747 (19%) of 3862 in the control group with known vital status at the end of the trial had died. Time to death did not differ (hazard ratio [HR] 0.94, 95% CI 0.76-1.15). In a preplanned subgroup analysis of patients with baseline CD4 counts of 201-350 cells per mu L, mortality was slightly lower in the intervention group than in the control group (0.73, 0.54-1.00; p=0.052), but it did not diff er between groups in patients with baseline CD4 of 200 cells per mu L or less (0.94, 0.76-1.15; p=0.577). In cohort 2, viral load suppression 12 months after enrolment was equivalent in intervention (2156 [71%] of 3029 patients) and control groups (2230 [70%] of 3202; risk difference 1.1%, 95% CI-2.4 to 4.6).
Interpretation Expansion of primary-care nurses’ roles to include ART initiation and represcription can be done safely, and improve health outcomes and quality of care, but might not reduce time to ART or mortality.”
“Midazolam is a benzodiazepine derivative drug that has powerful anxiolytic, amnestic, hypnotic, and sedative properties.